Gruenderfonds Ruhr
VC Fund
Essen, Germany
Gruenderfonds Ruhr is an investment firm.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Gruenderfonds Ruhr invests in
Stages Gruenderfonds Ruhr invests in
Countries Gruenderfonds Ruhr invests in
Round sizes
Round size
- Seed
- $9.1M–$10M
- Series A
- $5.3M–$98M
- Series B
- $11M–$16M
Investment Focus
Industry
- Health Care 2 (17%)
- Biotechnology 2 (17%)
- Renewable Energy 2 (17%)
- Information Technology 2 (17%)
- SaaS 1 (8%)
Stage
- Series A 4 (33%)
- Seed 3 (25%)
- Series B 2 (17%)
- Pre-Seed 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
iDEL Therapeutics
|
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M / Seed / Mar 17, 2026 | |
Cyberdesk
|
Cyberdesk provides IT solutions and management. | Seed / Feb 06, 2026 | |
Factor2 Energy
|
Factor2 Energy builds CO₂-based geothermal power systems designed to deliver clean, scalable baseload energy without fracking, ultra-deep drilling, or water-intensive processes. | $9.1M / Seed / Sep 19, 2025 | |
Otter Energy Trading
|
Otter Energy Trading is creating a marketplace where producers and customers may exchange electricity automatically. | Pre-Seed / Jul 01, 2025 | |
Lidrotec
|
Lidrotec aim to expand the application potential of processing with ultra-short pulse lasers. | $13.5M / Series A / Jun 25, 2025 | |
talpasolutions
|
talpasolutions a predictive SaaS analytics provider for the mining industry that helps companies optimize machine performance, reduce breakdowns, and improve safety by making data more understandable. talpasolutions makes it possible for operators and machine manufacturers in heavy industry to use machine data that would have otherwise been lost.talpasolutions concentrates on building visualization and analysis applications for the industrial internet. In the first step, large amounts of data from the machines are recorded. Comprehendable visualizations allow for different stakeholders to understand relationships based on sensor data and contextual data and to react to critical information, which would otherwise have been buried in the data transfer. In the second step the newest predictive models are applied to eliminate events such as errors and the breakdown of machines critical to the process. This increases not only the availability but also the workload of the machines. talpasolutions has built a network out of industry partners to develop solutions that stretch across various sectors and unify industry experience, data science, and workflow connectivity. Using predictive instructions our platform recognizes problems before they occur and supports users with workflow-based processes. Our applications make it possible to collect performance data from machines in order to recommend optimal fleet combinations for respective scenarios to customers. This leads to more operating hours, higher efficiency, and an improved lifetime value of the machines. | $16.3M / Series B / Mar 28, 2023 | |
|
Lidrotec
|
Lidrotec aim to expand the application potential of processing with ultra-short pulse lasers. | $5.3M / Series A / Dec 20, 2022 | |
VMRay
|
The VMRay Platform is a breakthrough solution for dynamic analysis of advanced threats, including zero day and targeted attacks. By surmounting inherent flaws that plague other products, VMRay Analyzer has become the gold standard for malware sandboxing among leading DFIR teams worldwide.The core of the VMRay Platform is an agentless,hypervisor-based sandbox, which is unique in combining near-total evasion resistance with full visibility into malware behavior: a trait we call X-Ray Vision. Because nothing touches or modifies the analysis environment, monitoring is invisible, and even the most evasive malware strains fully execute in the sandbox. By monitoring every interaction between malware and the target system, VMRay captures a complete and accurate record of threat behavior – data that enriches detection, incident response, digital forensics, and threat intelligence. VMRay Intelligent Monitoring excels over other solutions in distinguishing between malicious behavior and legitimate activity. As a result, VMRay Analyzer delivers precise, noise-free output that reduces false positive rates to near zero. This shortens investigations, enhances efficiency and prevents legitimate traffic from being blocked | $11.1M / Series B / Dec 19, 2022 | |
Emergence Therapeutics
|
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. | $98.1M / Series A / Dec 07, 2021 | |
Abalos Therapeutics
|
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability tore-program the immune system to specifically and efficiently eliminate the malignant tumor tissue. | $35.9M / Series A / Oct 14, 2021 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Gruenderfonds Ruhr invest in?
Gruenderfonds Ruhr invests primarily in Health Care, Biotechnology and Renewable Energy startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gruenderfonds Ruhr's check size?
Gruenderfonds Ruhr typically joins rounds of $9.1M–$10M at Seed, $5.3M–$98M at Series A and $11M–$16M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gruenderfonds Ruhr participates in.
When did Gruenderfonds Ruhr last invest?
The most recent investment recorded for Gruenderfonds Ruhr closed in Mar 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
